Bayer Halts Three Non-CABG Trasylol Studies
This article was originally published in The Pink Sheet Daily
Decision to discontinue trials in certain types of cancer patients was not related to safety concerns, firm maintains.
You may also be interested in...
Changes are the result of September advisory committee meeting, concerns over renal dysfunction.
The company will publish findings of independent investigation, which could recommend corrective action plan.
FDA’s Cardiovascular & Renal Drugs Advisory Committee reiterate risk of renal dysfunction associated with aprotinin at its Sept. 21 meeting.